Stocks
CG Oncology, Inc.CGON
NASDAQHealthcareBiotechnology$61.71
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing oncolytic immunotherapies for the treatment of cancer, with its lead candidate, cretostimogene grenadenorepvec, targeting bladder cancer. The company is advancing its pipeline through clinical trials, and its progress is closely watched by investors given the potential of its therapy to address high unmet medical needs in oncology.
52W Range: $35.80-$80.97
Congressional Interest in CG Oncology, Inc. (CGON)
No congressional trades have been disclosed for CG Oncology, Inc. (CGON) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading CGON?
No congressional trades found for this stock.